To address our hypothesis that Nurr1 is a promising molecular target for intervention in PD, we previously established high throughput screening systems to detect activators of Nurr1 and identified three compounds (i.e., CQ, AQ, and glafenine) that share an identical scaffold 4A7C. The gene discussed is NR4A2; the disease is Parkinson disease.